Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

BENGALURU: Biocon Foundation has unveiled a breathtaking public art spectacle, turning over 50 Metro pillars between Huskur ...

Peter Bains, Group CEO of Biocon, talks about India's budget, and the impact of its plans to cut or remove duties on ...

Biocon Foundation transforms metro pillars into art celebrating Bengaluru's unsung heroes, merging heritage with urban landscape.

Adjusting for these factors, Biocon’s Q3 FY25 revenue saw a 10 per cent year-on-year growth. The company’s net research and development investments for the quarter stood at Rs 199 crore, representing ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and ...

Peter Bains, Group CEO of Biocon, discusses his outlook and strategy for business growth after the company's latest earnings, ...

Biocon plans to list its biosimilars business by March 2026, targeting a double-digit market share in the U.S. with five new ...

The University of Glasgow has launched an innovative and exciting new postgraduate study programme with Indian biopharmaceutical giant Biocon.

Hyderabad: Biopharma major Biocon plans to introduce five new biosimilars in the United States in the new fiscal year, ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

There is market share gain compared to last year. Any biosimilar might be able to take on a four-five or six player market, said Siddharth Mittal, CEO and MD, Biocon ...